Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01352728 | Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | completed | Phase 2 | 50 | Chinese University of Hong KongOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00906373 | A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver | completed | Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01834963 | P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. | unknown | Phase 2 | 66 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | May 18, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | unknown | Phase 2 | 50 | Guangxi Medical UniversityOTHER | 0 | May 9, 2018 | clinicaltrials |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | unknown | Phase 2 | 40 | Guangxi Medical UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | terminated | Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02311205 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)(COTSOM) | unknown | Phase 2 | 55 | Asan Medical CenterOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | withdrawn | Phase 2 | 0 | Delcath Systems Inc.INDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | terminated | Phase 2 | 1 | Justin SimsOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT03337841 | Pembrolizumab as Neoadjuvant Treatment in HCC | unknown | Phase 2 | 50 | Kindai UniversityOTHER | 0 | Nov 9, 2017 | clinicaltrials |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | terminated | Phase 2 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT01217034 | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib(TACTICS) | unknown | Phase 2 | 228 | Kindai UniversityOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02862015 | Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients(Oncothermia) | unknown | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT03316326 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | unknown | Phase 2 | 35 | National Taiwan University HospitalOTHER | 0 | Oct 20, 2017 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT03261791 | Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | terminated | Phase 2 | 24 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 42 | Hospital General de Ciudad RealOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT02007954 | Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma(DEBDOX) | completed | Phase 2 | 24 | Yale UniversityOTHER | 1 | Aug 11, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2018source: clinicaltrials